Vanda Pharmaceuticals Inc

NASDAQ:VNDA   3:59:59 PM EDT
18.43
+0.63 (+3.54%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.02B
Current PE43.88
Forward PE 28.8
2yr Forward PE 19
See more stats
Estimates Current Quarter
Revenue$71 Million
Adjusted EPS$0.17
See more estimates
10-Day MA$17.59
50-Day MA$16.85
200-Day MA$13.65
See more pivots

Vanda Pharmaceuticals Inc Stock, NASDAQ:VNDA

2200 Pennsylvania Avenue NW, Suite 300E, Washington, District of Columbia 20037
United States of America
Phone: +1.202.734.3400
Number of Employees: 292

Description

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.